2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association
Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised …
Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
DK McGuire, WJ Shih, F Cosentino… - JAMA …, 2021 - jamanetwork.com
Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect
cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the …
cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the …
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …
therapies in patients with type 2 diabetes mellitus and are associated with improved …
2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of …
SR Das, BM Everett, KK Birtcher, JM Brown… - Journal of the American …, 2020 - jacc.org
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …
Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US
Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduce deaths
from cardiovascular conditions, hospitalizations for heart failure, and progression of kidney …
from cardiovascular conditions, hospitalizations for heart failure, and progression of kidney …
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular …
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …
structure and duration of action and have been studied in trials of varying sizes and with …
Heart failure with reduced ejection fraction: a review
Importance Worldwide, the burden of heart failure has increased to an estimated 23 million
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …
KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease
IH de Boer, ML Caramori, JCN Chan… - Kidney …, 2020 - kidney-international.org
This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …